Anticoag

Question 1

CHA2DS2VASc

Answer 1

CHF
Hypertension
Age over 75
Diabetes
Stroke
Vascular disease
Age 65-74
Sex (female)

Question 2

HAS-BLED

Answer 2

Hypertension (uncontrolled >160)
abnormal liver/renal fxn
stroke
bleeding
elderly over 65
drugs or alcohol

Question 3

what was the ARISTOTLE trial comparing and what was the outcome?

Answer 3

apixaban vs. warfarin for afib. apixaban was superior to warfarin in preventing stroke, embolism, and had less bleeding and lower mortality

Question 4

what was the AMPLIFY trial comparing and what was the outcome?

Answer 4

different dosing for apixaban for VTE. Apixaban 10mg BID for 7 days followed by 6 months 5mg BID is adequate therapy to treat an acute VTE

Question 5

what did the ADVANCE trial compare and what was the outcome?

Answer 5

apixaban versus enoxaparin for VTE prophylaxis. apixaban had less risk of bleeding compared to enoxaparin

Question 6

what was the outcome of the ROCKET-AF trial?

Answer 6

rivaroxaban was noninferior to warfarin for stroke/embolism in afib

Question 7

what was the EINSTEIN trial comparing and what was the outcome?

Answer 7

rivaroxaban vs. enoxaparin followed by warfarin for acute, symptomatic VTE. rivaroxaban was noninferior

Question 8

what was the RE-COVER trial comparing and what was the outcome?

Answer 8

dabigatran vs. warfarin for acute VTE. Dabigatran had similar efficacy to warfarin and a similar safety profile